



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/618,596	07/17/2000	Robert A. Macina	DEX-0075	8607
75	7590 04/27/2004		EXAMINER	
Kathleen A. Tyrell			HARRIS, ALANA M	
Law Offices Of Jane Massey Licata 66 E Main Street			ART UNIT	PAPER NUMBER
Marlton, NJ 08053			1642	
			DATE MAILED: 04/27/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/618,596	MACINA ET AL.			
		Examiner	Art Unit			
		Alana M. Harris, Ph.D.	1642			
Period fo	The MAILING DATE of this communication	appears on the cover sheet wit	h the correspondence address			
A SH THE - Exte after - If the - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR RIMAILING DATE OF THIS COMMUNICATION of time may be available under the provisions of 37 CF SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, or period for reply is specified above, the maximum statutory per to reply within the set or extended period for reply will, by steply received by the Office later than three months after the red patent term adjustment. See 37 CFR 1.704(b).	ON. FR 1.136(a). In no event, however, may a ren. a reply within the statutory minimum of thirty eriod will apply and will expire SIX (6) MONT statute, cause the application to become AB.	ply be timely filed (30) days will be considered timely. HS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on (02 February 2004.				
2a)[☐	This action is FINAL . 2b)⊠	This action is non-final.				
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposit	on of Claims					
5)□ 6)⊠ 7)□	Claim(s) 1 is/are pending in the application 4a) Of the above claim(s) is/are with Claim(s) is/are allowed. Claim(s) 1 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and	ndrawn from consideration.				
Applicati	on Papers					
10)	The specification is objected to by the Exar The drawing(s) filed on is/are: a) Applicant may not request that any objection to Replacement drawing sheet(s) including the co The oath or declaration is objected to by th	accepted or b) objected to be the drawing(s) be held in abeyand prection is required if the drawing(ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).			
Priority ι	ınder 35 U.S.C. § 119					
12)[_ a)[Acknowledgment is made of a claim for form All b) Some * c) None of: 1. Certified copies of the priority docum 2. Certified copies of the priority docum 3. Copies of the certified copies of the application from the International Butter the attached detailed Office action for a	nents have been received. nents have been received in Ap priority documents have been in ureau (PCT Rule 17.2(a)).	oplication No received in this National Stage			
Attachmen	t(s)					
1) Notice	e of References Cited (PTO-892)		ummary (PTO-413)			
2) Notice	e of Draftsperson's Patent Drawing Review (PTO-948 nation Disclosure Statement(s) (PTO-1449 or PTO/SI r No(s)/Mail Date <u><i>March</i> 19, 2004</u> .	, — — ·	/Mail Date formal Patent Application (PTO-152)			

Application/Control Number: 09/618,596 Page 2

Art Unit: 1642

DETAILED ACTION

Response to Amendments and Arguments

1. Claim 1 is pending.

Claim 1 has been amended.

Claim 1 is examined on the merits.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Withdrawn Rejection

Claim Rejections - 35 USC § 112

4. The rejection of claim 1 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is withdrawn. Claims 2-5 have been cancelled.

New Grounds of Rejection

Claim Rejections - 35 USC § 112

- 5. Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- a. Claim 1 is vague and indefinite in the recitation "determining levels of a colon specific gene (CSG)". It is unclear how the level of the gene is measured. What seems to be the claimed invention is the detection of a polynucleotide sequence

Application/Control Number: 09/618,596

Art Unit: 1642

comprising SEQ ID NO: 1 and the corresponding polypeptide. Applicants are advised to clearly and distinctly limit the claim language to the claimed invention.

Double Patenting

6. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

7. Claim 1 is provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of copending Application No. 09/700,769 (filed January 4, 2001). Although the conflicting claims are not identical, they are not patentably distinct from each other because both read on determining or measuring levels of CSG in a sample of cells, tissue or bodily fluid in order to assess the presence of colon cancer. While the instant application, 09/618,596 specifies that the CSG comprises a polynucleotide sequence of SEQ ID NO: 1 or the encoded polypeptide the broad claim of application '769 encompasses any CSG. The method of application '769 utilizing the broadly termed CSG includes a plethora of molecules and intrinsically reads on the instant application. This is a provisional

Page 4

Application/Control Number: 09/618,596

Art Unit: 1642

obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571) 272-0831. The examiner works a flexible schedule, however can normally be reached between the hours of 7:00 am to 4:30 pm, with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne "Bonnie" Eyler, Ph.D. can be reached on (571) 272-0871. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ALANA M. HARRIS, PH.D. PRIMARY, EXAMINER

Alana M. Harris, Ph.D.

26 April 2004